# Advances and Emerging Techniques in Transarterial Chemoembolization for Hepatocellular Carcinoma

## TL;DR

This paper reviews recent advances in transarterial chemoembolization (TACE) for treating hepatocellular carcinoma, focusing on new techniques and combination therapies that improve outcomes.

## Contribution

The paper introduces novel TACE combination therapies and updated prognostic models for hepatocellular carcinoma treatment.

## Key findings

- Enhanced TACE techniques with new materials and procedural methods show promising results.
- Combining TACE with radiation, ablation, and immunotherapy is advancing treatment options.
- New prognostic models are helping to reshape the treatment landscape for hepatocellular carcinoma.

## Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and is often asymptomatic until late-stage disease when treatment options are limited. Surgical resection and transplantation remain the gold standard for early-stage disease. However, these are not options for those presenting in later stages or those with prohibitive surgical risk. Transarterial chemoembolization (TACE) is a first-line treatment recommendation for patients with intermediate-stage disease and advances are looking to expand treatment indications and improve outcomes. Enhanced TACE techniques with new materials and procedural methods have already shown promising results. Novel TACE combination therapies with radiation, ablation, and immunotherapy are looking to advance this area further. This review will highlight advances in TACE, summarize new prognostic models and discuss future directions with HCC treatment.

HCC is the third leading cause of cancer-related death, which carries a low 5-year survival rate, in part due to many patients presenting in late-stage disease. Surgical resection and liver transplantation are first-line treatments for early-stage disease, offering the chance for curative resection and, in the case of transplantation, elimination of the underlying disease process. However, due to either late-stage presentation or prohibitive surgical risk, many patients are not candidates for such treatments. Locoregional therapies, including TACE, provide treatment options for these patients. TACE is a first-line treatment recommendation for intermediate-stage disease, and in certain clinical situations it is appropriate in earlier and later stages. Improved treatment efficacy and expanded recommendations for TACE are a result of advances in the procedural technique, materials, and combination therapies. Promising combination therapies employ TACE with radiation, ablation and novel immunotherapies. When combined with new prognostic models, the treatment landscape for HCC continues to change. This review will summarize advanced TACE techniques and the new TACE combination therapies, before looking ahead at prognostic models being developed and future directions with HCC treatment.